Stocks · Healthcare · Medical - Instruments & Supplies
ICU Medical, Inc. ICUI
$159.38 +1.40% Close, Oct 2, 2026 · NASDAQ · Market cap $3.98B
Next earnings report: Nov 5, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Earnings beat analyst estimates in each of the last 14 quarters (average surprise over the last four: +22.6%).
- Net debt is 3.3× EBITDA, a high level of leverage.
- The stock is in an uptrend: above its 200-day average for 84 trading days, with the 50-day average above the 200-day.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 20%
- FCF growth (TTM, YoY)Top 9%
- Revenue growth, 3-year CAGRBottom 21%
- Revenue growth accelerationTop 28%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 49%
- Gross marginBottom 25%
- Operating marginTop 34%
- Cash conversion (OCF / net income)Top 10%
- Accruals (lower is better)Bottom 44%
- Net debt / EBITDA (lower is better)Bottom 27%
- Interest coverTop 40%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 28%
- Free-cash-flow yieldTop 23%
- EBITDA / enterprise valueTop 20%
- Sales / enterprise valueTop 29%
- P/E vs own 5-year history (lower is better)Bottom 32%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 38%
- 6-month returnTop 32%
- 1-year return vs S&P 500Top 34%
- Distance from 52-week highTop 27%
- Trend checklist (0–4)Top 39%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 21%
- Consecutive EPS beatsTop 2%
- Share of analysts rating BuyTop 24%
- Upside to consensus price targetBottom 24%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 16%
- Maximum drawdown, 3 yearsTop 14%
- Beta vs S&P 500 (lower is better)Top 31%
- Net debt / EBITDA (lower is better)Bottom 27%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -10.9% | -9.0% | ↑ |
| Gross margin | 35.8% | 37.6% | ↑ |
| Operating margin | 2.9% | 5.0% | ↑ |
| FCF margin | 2.6% | 7.1% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -9.0% | -10.9% | ↑ | Bottom 20% |
| Gross margin | 37.6% | 35.8% | ↑ | Bottom 25% |
| Operating margin | 5.0% | 2.9% | ↑ | Top 34% |
| Net margin | 1.4% | -1.6% | ↑ | — |
| Free-cash-flow margin | 7.1% | 2.6% | ↑ | — |
| Return on invested capital | -21.7% | — | Bottom 49% | |
| Revenue growth, 3-year CAGR | -0.7% | — | Bottom 21% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 3.00×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -5.2%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 1.9%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +8.7 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- 3.27×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 1.3×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- 0.21%
- Shareholder yield
- 0.21%
- Share count change, 1 year
- +1.4%
- Share count change, 3-year CAGR
- +1.3%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 6, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 14
- Beats in the last 8 reports
- 8 of 8
- Average EPS surprise, last 4
- +22.6%
- Average 2-day reaction, last 8
- +1.1%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $186.40
- Target vs current price
- +17.0%
- Analysts with a rating
- 12
- Share rating Buy or Strong Buy
- 92%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 6, 2026 | +24.1% | -0.0% | +7.8% | +2.1% | — |
| May 7, 2026 | +10.7% | +2.9% | +2.0% | +12.8% | +44.6% |
| Feb 19, 2026 | +13.7% | -1.2% | +2.3% | -17.4% | -18.9% |
| Nov 6, 2025 | +42.0% | +1.8% | +9.2% | +11.8% | +18.3% |
| Aug 7, 2025 | +45.8% | +2.4% | -10.1% | -1.0% | -5.6% |
| May 8, 2025 | +39.8% | +6.2% | +1.1% | -1.2% | -3.3% |
| Feb 27, 2025 | +42.6% | -2.9% | -6.9% | -3.6% | -15.3% |
| Nov 12, 2024 | +27.2% | -0.1% | -4.7% | -10.2% | -10.4% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | $2.37 | $1.91 | +24.1% | $547.9M |
| May 7, 2026 | $1.97 | $1.78 | +10.7% | $525.8M |
| Feb 19, 2026 | $1.91 | $1.68 | +13.7% | $535.9M |
| Nov 6, 2025 | $2.03 | $1.43 | +42.0% | $537.0M |
| Aug 7, 2025 | $2.10 | $1.44 | +45.8% | $548.9M |
| May 8, 2025 | $1.72 | $1.23 | +39.8% | $604.7M |
| Feb 27, 2025 | $2.11 | $1.48 | +42.6% | $629.8M |
| Nov 12, 2024 | $1.59 | $1.25 | +27.2% | $589.1M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 135.1× | 82.6× | 63th | Top 28% |
| P/E (forward) | 18.2× | — | — | — |
| EV / EBITDA | 16.7× | — | — | Top 20% |
| EV / Sales | 2.30× | — | — | Top 29% |
| Free-cash-flow yield | 3.84% | — | — | Top 23% |
| Earnings yield | 0.74% | — | — | Top 28% |
P/E over the past five years
Range 40.0× – 396.0× since Jun 30, 2021. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✓ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 84
- 50-day average slope (20 days)
- +1.3%
- 200-day average slope (20 days)
- +1.1%
- Distance from 50-day average
- -5.7%
- Distance from 200-day average
- +8.4%
- RSI (14)
- 43.7
- Relative volume
- 0.89×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 34.9%
- Volatility vs own 5-year history
- 30th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.79
- Correlation with S&P 500
- 0.33
- Current drawdown from 1-year high
- -14.9%
- Maximum drawdown, 3 years
- -41.2%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Sep 8, 2021 | Nov 9, 2023 | -68.8% | 547 days | Not yet recovered |
| Jan 11, 2021 | Aug 12, 2021 | -16.1% | 148 days | 18 days (Sep 8, 2021) |
| Oct 15, 2020 | Oct 30, 2020 | -12.2% | 11 days | 32 days (Dec 16, 2020) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $3.98B
- P/E (TTM)
- 135.1
- EPS, diluted (TTM)
- $1.18
- Revenue (TTM)
- $2.16B
- 52-week range
- $112.50 – $192.85
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $1.32B | $2.28B | $2.26B | $2.38B | $2.23B |
| Gross profit | $491.5M | $697.8M | $739.9M | $824.8M | $819.7M |
| Operating income | $123.2M | -$42.9M | $22.8M | $43.0M | $107.0M |
| Net income | $103.1M | -$74.3M | -$29.7M | -$117.7M | $732,000 |
| EPS (diluted) | $4.74 | -$3.11 | -$1.23 | -$4.83 | $0.03 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $589.1M | $629.8M | $604.7M | $548.9M | $537.0M | $540.3M | $530.4M | $551.7M |
| Net income | -$33.0M | -$23.8M | -$15.5M | $35.3M | -$3.4M | -$15.7M | $30.1M | $19.1M |
| EPS (diluted) | -$1.35 | -$0.97 | -$0.63 | $1.43 | -$0.14 | -$0.64 | $1.20 | $0.76 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $267.5M | -$62.1M | $166.2M | $204.0M | $179.8M |
| Capital expenditure | -$81.2M | -$99.3M | -$93.7M | -$79.4M | -$88.0M |
| Free cash flow | $186.4M | -$161.5M | $72.5M | $124.7M | $91.8M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $9.4M | $8.8M | -$5.3M | -$1.1M | -$2.7M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $298.3M
- Total assets
- $3.97B
- Total liabilities
- $1.82B
- Total debt
- $1.27B
- Net debt
- $973.3M
- Shareholders’ equity
- $2.15B
As of Jun 30, 2026 (filed Aug 6, 2026).
Short interest
- Shares sold short
- 1,515,688
- Days to cover
- 6.29
- Change vs previous report
- +5.8%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Mar 18, 2002
- 3-for-2
- Apr 1, 1993
- 3-for-2